Biotech company Moderna expects about 20 million doses of its experimental coronavirus vaccine to be ready to ship in the US by the end of this year.
According to company officials, the Massachusetts-based drug developer will prepare to distribute the vaccine, dubbed mRNA-1273, across the country if their end-stage clinical research demonstrates that it works and is federally approved.
“From a distribution perspective, we are ready,” Dr. Tal Zaks, Moderna’s chief medical officer, told investors on Thursday’s conference call. “We expect the mRNA-1273 to be distributed in the existing infrastructure. Nothing new needed has not been used for many years with many other vaccines.
WE ARE HIGH-RECORDED ONLY DATE ERRORS
Moderna says it is “actively preparing”; for the launch of the vaccine, which is one of four undergoing phase 3 clinical trials in the US. The company drew in 30,000 study participants and said it might have enough data to apply for urgent approval of the footage by the end of November.
In its third-quarter earnings report, Moderna said it has received more than $ 1.1 billion in vaccine deposits from governments around the world, including $ 600 million from the U.S. Agreement to buy up to 500 million doses.
According to chief financial officer David Meline, the company is expected to deliver on those commitments well by delivering about 500 million to 1 billion injectable doses by 2021.
CLICK HERE TO COMPLETE CORONAVIRUS INSURANCE
But it all depends on whether phase 3 of the vaccine is successful and whether the Food and Drug Administration will eventually approve the injection. Moderna plans to conduct the first analysis of the efficacy of the vaccine as 53 participants developed symptomatic cases of COVID-19, which could pave the way for the company to get approval. application from federal.
“I believe that if we roll out COVID-19, 2021 could be the most important year in Moderna’s history,” CEO Stéphane Bancel said in a statement.
Click to know more from The New York Post.